FDA approves Amphastar’s iron sucrose injection for CKD-associated anemia, with potential for $80-100 million sales and a 2025 launch.
Latest Ratings for AMPH
DateFirmActionFromTo Mar 2022Piper SandlerMaintainsOverweight Jan 2022Piper SandlerUpgradesNeutralOverweight Mar 2021Wells FargoMaintainsEqual-Weight